

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Adnan M.M. Mjalli et al.

Serial No.

10/091,759

Filing Date

March 5, 2002

For

Carboxamide Derivatives as Therapeutic Agents

Examiner

O'Sullivan, P.

Art Unit

1621

Atty. Docket:

TTP 2001-21

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450


## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08a. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

$\boxtimes$	1.	the U	Information Disclosure Statement is being filed within three months of U.S. filing date OR before the mailing date of a first Office Action on the is. No certification or fee is required.
	2.	after on the	Information Disclosure Statement is being filed more than three months the U.S. filing date AND after the mailing date of the first Office Action e merits, but before the mailing date of a Final Rejection or Notice of wance.
		a.	I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
		b.	I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual

		designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e)(2).
	c.	Please debit Deposit Account No. 50-3216 in the amount of \$in payment of the fee under 37 C.F.R. § 1.17(p). Two duplicate copies of this paper are attached.
3.	after the Notice hereby Please payme	information Disclosure Statement is being filed more than three months the U.S. filing date and after the mailing date of a Final Rejection or of Allowance, but on or before payment of the Issue Fee. Applicant(s) petition(s) that the Information Disclosure Statement be considered. debit Deposit Account No. 50-3216 in the amount of \$ in the of the petition fee under 37 C.F.R. § 1.17(p). Two duplicate copies paper are attached.
	a.	I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more that three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
	b.	I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e)(2).
4.	was fir counte individ	tem of information contained in this Information Disclosure Statement est cited in a communication from a foreign patent office in a rpart application and this communication was not received by any lual designated in § 1.56(c) more than thirty days prior to the filing of formation disclosure statement. 37 C.F.R. § 1.704(d).





Date: 1005

Respectfully submitted,

Samuel B. Rollins

Registration No. 52,180

TransTech Pharma, Inc. 4170 Mendenhall Oaks Pkwy Suite 110

High Point, NC 27265 Phone: (336) 841-0300 Fax: (336) 841-0310

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ubstitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/091,759			
Filing Date	March 5, 2002			
First Named Inventor	Adnan M.M. Mjalli et al.			
Art Unit	1621			
Examiner Name	O'Sullivan, P.			
Attorney Docket Number	TTP 2001-21			

			U.S. PATENT	OCUMENTS	
Examiner Initials *	Cite No. <sup>1</sup>	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
		US- 6,613,801	09/02/2003	Mjalli et al.	
•		US- 20040097407	05/20/2004	Mjalli et al.	
		US-			
		US-		1	
		US-			1000
		US-			
		US-			
		US-		1	
	· · · · · ·	US-	····		
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite No.1	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )				
	<del> </del>					
	<del></del>					
	<u> </u>					

Examiner Date Signature Considered			
Constant	Examiner Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patient Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.